You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
药明生物(02269.HK)与BioVaxys签署生物生产协议
阿思达克 03-16 10:37
药明生物(02269.HK)与加拿大生物技术公司BioVaxys Technology签署生物生产协议,双方将生产BioVaxys的新冠肺炎候选疫苗BVX-0320及Covid-T免疫诊断项目所需的SARS-CoV-2病毒S蛋白。

药明生物将合成高产量的完全表徵GLP级SARS-CoV-2病毒S蛋白,用於BioVaxys的COVID-T诊断方法临床前安全性研究。重组S蛋白将利用药明生物的专有技术载体构建和表达,并在中试装置反应器中进行高产蛋白生产。

BioVaxys表示,通过建立自家S蛋白来源,将能够确保美国食品和药物管理局(FDA)要求的纯度、一致性和蛋白质表征,以及自行提供蛋白的经济性,促进用於人体试验的GMP级S蛋白未来生产和未来商业规模生产。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account